menu
    • menu
    [{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioDelivery Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Solution","sponsorNew":"BioDelivery Sciences \/ BioDelivery Sciences","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ BioDelivery Sciences"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioDelivery Sciences \/ BioDelivery Sciences","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ BioDelivery Sciences"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Alvogen"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"Collegium Pharmaceutical \/ Collegium","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Collegium"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Collegium Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tapentadol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ironshore Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ironshore Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Collegium Pharmaceutical

    Menu

    Collegium Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium Completes Acquisition of Ironshore Therapeutics

                            Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.

                            Brand Name : Jornay PM

                            Molecule Type : Small molecule

                            Upfront Cash : $525.0 million

                            September 04, 2024

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : $550.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

                            Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.

                            Brand Name : Jornay PM

                            Molecule Type : Small molecule

                            Upfront Cash : $525.0 million

                            July 29, 2024

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : $550.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tapentadol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Collegium Announces Authorized Generic Agreement with Hikma for Nucynta® and Nucynta® ER

                            Details : Through the agreement, Collegium will exclusively manufacture and supply Hikma with all authorized generic products for sale, including Nucynta-Generic (tapentadol HCl).

                            Brand Name : Nucynta-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 29, 2024

                            Lead Product(s) : Tapentadol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference

                            Details : ELYXYB™ (celecoxib) oral solution is prescription nonsteroidal anti-inflammatory drug (NSAID) used for the acute treatment of migraine with or without aura in adult.

                            Brand Name : Elyxyb

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2022

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : BioDelivery Sciences

                            Deal Size : $604.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium Completes the Acquisition of BDSI

                            Details : Diversifies and expands Collegium’s revenues by adding BELBUCA® as a second and highly complementary growth driver to Collegium’s highly differentiated pain portfolio, in addition to a contributor with SYMPROIC®, and a new product launch opportunit...

                            Brand Name : Belbuca

                            Molecule Type : Small molecule

                            Upfront Cash : $604.0 million

                            March 22, 2022

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : BioDelivery Sciences

                            Deal Size : $604.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : BioDelivery Sciences

                            Deal Size : $604.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

                            Details : Diversifies and expands Collegium’s revenues by adding BELBUCA as a second and highly complementary growth driver to Collegium’s highly differentiated pain portfolio, in addition to a contributor with Symproic, and a new product launch opportunity wi...

                            Brand Name : Belbuca

                            Molecule Type : Small molecule

                            Upfront Cash : $604.0 million

                            February 14, 2022

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : BioDelivery Sciences

                            Deal Size : $604.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BioDelivery Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            BioDelivery Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Alvogen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Unti...

                            Details : BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

                            Brand Name : Belbuca

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2021

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Alvogen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BioDelivery Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            BioDelivery Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S....

                            Details : BDSI intends to launch ELYXYB in the first quarter of 2022. Additionally, BDSI plans to conduct an ELYXYB pediatric study, which will have the potential to address the significant unmet needs of pediatric and adolescent patients suffering from migraine a...

                            Brand Name : Elyxyb

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 09, 2021

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BioDelivery Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            BioDelivery Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : $15.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the...

                            Details : ELYXYB is an oral solution of celecoxib, formulated using a self-micro emulsifying drug delivery system that improves solubility and bioavailability of the drug leading to better absorption.

                            Brand Name : Elyxyb

                            Molecule Type : Small molecule

                            Upfront Cash : $6.0 million

                            August 04, 2021

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : $15.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            BioDelivery Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            BioDelivery Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 NANS Mee...

                            Details : Data from a placebo-controlled study compared safety outcomes of BELBUCA® versus oral oxycodone. BELBUCA® is a buprenorphine buccal film is indicated for the management of severe pain.

                            Brand Name : Belbuca

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 15, 2021

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth